featured
Adjuvant Pembrolizumab vs Placebo in Resected Stage III Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adjuvant Pembrolizumab Versus Placebo in Resected Stage III Melanoma
N. Engl. J. Med 2018 Apr 15;[EPub Ahead of Print], AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, A Haydon, M Lichinitser, A Khattak, MS Carlino, S Sandhu, J Larkin, S Puig, PA Ascierto, P Rutkowski, D Schadendorf, R Koornstra, L Hernandez-Aya, M Maio, AJM van den Eertwegh, JJ Grob, R Gutzmer, R Jamal, P Lorigan, N Ibrahim, S Marreaud, ACJ van Akkooi, S Suciu, C RobertFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.